The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women
Authors:
- 20 October 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 8 (6) , 769-784
Abstract
(2015). The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women. Expert Review of Clinical Pharmacology: Vol. 8, No. 6, pp. 769-784. doi: 10.1586/17512433.2015.1099432Keywords
This publication has 115 references indexed in Scilit:
- Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 yearsOsteoporosis International, 2012
- European guidance for the diagnosis and management of osteoporosis in postmenopausal womenOsteoporosis International, 2012
- Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysisOsteoporosis International, 2012
- Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year dataOsteoporosis International, 2012
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)Journal of Bone and Mineral Research, 2011
- Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?Osteoporosis International, 2011
- Defining Ethnic and Racial Differences in Osteoporosis and Fragility FracturesClinical Orthopaedics and Related Research, 2011
- A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®Osteoporosis International, 2011
- Exposure to Oral Bisphosphonates and Risk of Esophageal CancerJAMA, 2010
- Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent FracturesArchives of internal medicine (1960), 2004